Desert King
  • Home
  • About Us
  • Raw Materials
    • Quillaja Management
    • Yucca Management
    • Jojoba Management
  • Lines of Business
    • Pharmaceuticals
    • Animal Nutrition and Health
    • Food and Beverages
    • Personal Care and Cosmetics
    • Agriculture
    • Environment and Mining
  • Quality
  • News
  • Contact
  • English
  • Spanish
The Natural Choice The Natural Choice The Natural Choice The Natural Choice
  • Home
  • About Us
  • Raw Materials
    • Quillaja Management
    • Yucca Management
    • Jojoba Management
  • Lines of Business
    • Pharmaceuticals
    • Animal Nutrition and Health
    • Food and Beverages
    • Personal Care and Cosmetics
    • Agriculture
    • Environment and Mining
  • Quality
  • News
  • Contact
  • English
  • Spanish

Archives

Desert King leads quillay traceability and sustainable management with FSC® certification 
0
By Desert King
In Publications
Posted 25 September, 2025

Desert King leads quillay traceability and sustainable management with FSC® certification 

Responsible Management:  Desert King leads quillay traceability and sustainable management with FSC® certification  The company is the only one in the quillay industry to hold FSC® Chain of [...]

READ MORE
Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China. Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the [...]

READ MORE
Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192. PMID: 40804241 This study supports a [...]

READ MORE
Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30. PMID: 40737310 LeishTec is a recombinant vaccine adjuvanted [...]

READ MORE
Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396. PMID: 40592255 This study [...]

READ MORE
Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, [...]

READ MORE
Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.
0
By Desert King
In Scientific Papers
Posted 15 September, 2025

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, [...]

READ MORE

DESERT KING INTERNATIONAL
745 Main Street-
Chula Vista, CA, USA, 91911
+1 619 429 5222
info@desertking.com

DESERT KING CHILE
Avenida Industrial 1970
Quilpué, Chile, 2420505
+56 32 292 5020
info@desertking.cl

DESERT KING MEXICO
Camino Vecinal 11500-A
Tijuana B.C., México, 22664
+52 664 636 11 24
info@desertkingmexico.com

Privacy Policy
© 2025 Desert King. All Right Reserved

Start typing and press Enter to search